《新股消息》藥明合聯(02268.HK)公開發售上限定價20.6元 一手中籤率13%
由藥明生物(02269.HK)分拆的藥明合聯(02268.HK)公布招股結果,每股發售價定為20.6元,為招股價範圍(19.9至20.6元)的上限定價。香港公開發售部分錄得超額認購約48.96倍。每手500股計,一手中籤率13%,認購8手即4,000股穩獲一手。該股將於明日(17日)掛牌。聯席保薦人為摩根士丹利、高盛及摩通。
公司上市引入7名基石投資者,包括Invesco、General Atlantic Singapore Fund 、卡塔爾主權財富基金卡塔爾投資局附屬Al-Rayyan Holding、UBS AM Singapore、HongShan Funds、Novo Holdings、清池資本(香港)旗下Lake Bleu Prime,共認購1.14億股公司股份,約佔緊隨全球發售完成後公司已發行股本9.67%。
此外,公司上市料淨集資約34.83億元,當中約67%將用於在新加坡興建生產設施及擴大在中國的抗體中間體產能;約23%將用於有選擇地尋求戰略聯盟、投資及收購機會,以主要擴大公司的技術平台及服務類型以及能力;約10%用作營運資金及其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.